Author

M. V. Ortiz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. G. Henssen· 2 shared A. Eggert· 1 shared A. Kentsis· 1 shared A. L. Kung· 1 shared A. Letai· 1 shared A. Lissat· 1 shared A. M. Wengner· 1 shared A. Makohon-Moore· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. G. Henssen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJan 5, 2023

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma

M. D. Kinnaman, S. Zaccaria, A. Makohon-Moore…·C. A. Iacobuzio-Donahue

This study identifies subclonal copy number alterations in relapsed osteosarcoma, showing MYC gain/amplification in treatment-resistant clones and their emergence before chemotherapy.

DOI 10.1101/2023.01.05.522765

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 4, 2020

Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

H. Dorado Garcia, Y. Bei, J. von Stebut…·A. G. Henssen

This study identifies ATR as a synthetic lethal target in PAX3-FOXO1-driven rhabdomyosarcoma, showing ATR inhibition enhances PARP inhibitor efficacy and is tolerated in patients.

DOI 10.1101/2020.12.04.411413

humangenetic perturbation / CRISPR

𝕏 PostBluesky

Cancer BiologybioRxivDec 30, 2018

Prohibitin is a prognostic marker of relapse and therapeutic target to block chemotherapy resistance in Wilms tumor

M. V. Ortiz, S. Ahmed, M. Burns…·A. Kentsis

This study identifies prohibitin as a urine biomarker for Wilms tumor relapse and shows it promotes chemotherapy resistance by disrupting mitochondrial apoptosis.

DOI 10.1172/jci.insight.127098

humanproteomics

𝕏 PostBluesky